35 active not recruiting. 35 Phase 2, 7 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 35 | Active not recruiting 35 |
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease Ergocalciferol 50,000 IU, Methimazole - Graves Disease, Graves' Disease | Phase 2 | Active not recruiting | Northwell Health | 30 | 2025-08-25 | 2026-10-23 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection - Hypoparathyroidism | Phase 2 | Active not recruiting | MBX Biosciences | 60 | 2024-10-31 | 2026-10-07 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease AMG 732, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Active not recruiting | Amgen | 94 | 2024-05-30 | 2026-08-10 |
| A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants Armour Thyroid, Levothyroxine - Hypothyroidism | Phase 2 / Phase 3 | Active not recruiting | AbbVie | 2701 | 2024-04-26 | 2026-10-13 |
| Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors Dexmedetomidine Injection [Precedex] - Thyroid Neoplasms | Phase 2 / Phase 3 | Active not recruiting | South Egypt Cancer Institute | 80 | 2024-04-25 | 2026-02-25 |
| A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease TOUR006 - 20 MG, Placebo, TOUR006 - 50 MG - Thyroid Eye Disease | Phase 2 | Active not recruiting | Tourmaline Bio, Inc., a Novartis Company | 79 | 2024-02-19 | 2026-04-23 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer JK08, Pembrolizumab, Lenvatinib Pill - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Active not recruiting | Salubris Biotherapeutics Inc | 263 | 2022-10-17 | 2024-10-15 |
| Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Pembrolizumab - Thyroid Cancer | Phase 2 | Active not recruiting | Saad A Khan | 9 | 2022-02-15 | 2026-09-09 |
| Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer Lenvatinib, Pembrolizumab - Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2021-11-04 | 2026-08-10 |
| A Study of KL590586 in Patients With Advanced Solid Tumors KL590586 Capsule - Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 414 | 2021-09-15 | 2026-05-08 |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Spartalizumab, Tislelizumab - MSI-H Colorectal Cancer, Melanoma | Phase 2 | Active not recruiting | SOLTI Breast Cancer Research Group | 184 | 2021-04-12 | 2025-03-21 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer Binimetinib, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present | Phase 2 | Active not recruiting | Providence Health & Services | 24 | 2020-10-30 | 2026-04-13 |
| Laser Ablation of Papillary Thyroid Microcarcinoma Percutaneous Laser Ablation (PLA) - Papillary Thyroid Microcarcinoma, Thyroid | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 10 | 2020-10-19 | 2026-08-10 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2020-02-10 | 2026-07-31 |
Showing 20 of 35. Sign in to see all of them.
Thyroid Neoplasms (27) · Thyroid Cancer, Papillary (10) · Melanoma (7) · Sarcoma (7) · Carcinoma, Non-Small-Cell Lung (6) · Cholangiocarcinoma (6) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Adenocarcinoma, Follicular (4) · Breast Neoplasms (4) · Carcinoma, Medullary (4) · Colonic Neoplasms (4) · Salivary Gland Neoplasms (4) · Thyroid Carcinoma, Anaplastic (4)
Endocrine System Diseases (33) · Endocrine Gland Neoplasms (27) · Neoplasms by Site (27) · Head and Neck Neoplasms (26) · Neoplasms (26) · Neoplasms by Histologic Type (23) · Neoplasms, Glandular and Epithelial (23) · Carcinoma (22) · Adenocarcinoma (19) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Digestive System Diseases (11) · Digestive System Neoplasms (11)
Nivolumab (5) · pembrolizumab (5) · Magnetic Resonance Spectroscopy (4) · selpercatinib (4) · trametinib (4) · Specimen Handling (3) · dabrafenib (3) · CTLA-4 Antigen (2) · Disulfides (2) · Immunoglobulin G (2) · Ipilimumab (2) · Vemurafenib (2) · binimetinib (2) · entrectinib (2) · lenvatinib (2)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Memorial Sloan Kettering Cancer Center (4) · Eli Lilly and Company (3) · Hoffmann-La Roche (2) · AbbVie (1) · Amgen (1) · Arvinas Inc. (1) · Instituto do Cancer do Estado de São Paulo (1) · MBX Biosciences (1) · Merck Sharp & Dohme LLC (1) · Northwell Health (1) · Providence Health & Services (1) · SOLTI Breast Cancer Research Group (1) · Saad A Khan (1)
United States (27) · Spain (8) · France (6) · Italy (6) · Germany (5) · United Kingdom (5) · Australia (4) · Canada (4) · China (4) · Japan (4) · Puerto Rico (4) · South Korea (4) · Hong Kong (3) · Singapore (3) · Taiwan (3)
Eric Sherman, MD (2) · Maria E Cabanillas (2) · Alan L Ho (1) · Alan L Ho, MD, PhD (1) · Alexander Pearson (1) · Anwen Liu, Professor (1) · Bhavana Konda (1) · Camila MV Moniz, Doctor (1) · Christine A Pratilas (1) · Jing Li (1) · Keith T Flaherty (1)
PMID 31838007, PMID 37934000, PMID 40086048, PMID 26586415, PMID 29118225, PMID 30943124, PMID 31682550, PMID 31838015, PMID 31969335, PMID 31980466, PMID 32359091, PMID 32463741, PMID 32846060, PMID 32846061, PMID 32919526, PMID 33048619, PMID 33362722, PMID 33646820, PMID 33720068, PMID 33836153, PMID 33882143, PMID 34088726, PMID 34380663, PMID 34427452, PMID 34716198, PMID 34924145, PMID 34990208, PMID 35114169, PMID 35133871, PMID 35138919, PMID 35361487, PMID 35395680, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 35923928, PMID 35930972, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36200668, PMID 36351402, PMID 36657661, PMID 36748723, PMID 36924196, PMID 37053535, PMID 37265412, PMID 37315261, PMID 37322121
2015 (2), 2023 (2), 2017 (1), 2019 (1), 2025 (1), P30CA008748 (1), P30CA016672 (1), P50CA172012 (1), R01CA184724 (1), U10CA180820 (1), U10CA180886 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186712 (1)